1. Allgulander A, Lavori PW. Excess mortality among 3302 patients with " panic" anxiety neurosis. Arch Gen Psychiatry 1991;48:599-602.

2. Altshuler L. Bipolar disorder: Are repeated episodes associated with neuroanatomic and cognitive change. Biol Psychiatry 1993;33:563-565.

3. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: A controversy revisited. Am J Psychiatry 1995;152:1130-1138.

4. Baldessarini RJ, Tondo L, Faedda GL, Suppes T, Floris G, Rudas N. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 1996;57:441-448.

5. Blackburn IM, Eunson KM, Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and combination of both. J Affect Disord 1986;10:67-75.

6. Bondolfi G, Bauman P, Patris M, et al. A randomized double-blind trial of risperidone versus clozapine for treatment resistant chronic schizophrenia. Presented at the 148th Annual Meeting of the American Psychiatric Association, May, 1995, Miami, Florida.

7. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA 1994;271:918-924.

8. Calabrese JR, Bowden C, Woyshville MJ. Lithium and the anticonvulsants in the treatment of bipolar disorder. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology. The fourth generation of progress. New York: Raven Press, 1995.

9. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759-764.

10. Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992;12:53-56.

11. Carpenter WT, Jr, Heinrichs D. Early intervention, time limited, targeted pharmacotherapy of schizophrenia. Schizophr Bull 1983;9:533-542.

12. Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL. The enduring psychosocial consequences of mania and depression. Am J Psychiatry 1993;150:720-727.

13. Depression Guideline Panel. Depression in primary care; Vol. I. Treatment of major depression. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993. AHCPR Publication No. 93-0551.

14. Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993;50:448-455.

15. Faravelli C, Albanesi G. Agoraphobia with panic attacks; one-year prospective follow-up. Compr Psychiatry 1987;28:481-487.

16. Frank E, Johnson S, Kupfer DJ. Psychological treatments in the prevention of relapse. In: Montgomery S, Rouillon F, eds. Long-term treatment of depression. New York: John Wiley;1992:187-228.

17. Frank E, Kupfer DJ, Perel C, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-1099.

18. Gelenberg AJ, Kane JM, Keller MB. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989;321:1489-1493.

19. Glick ID, Burti L, Suzuki K, Sacks M. Effectiveness in psychiatric care: I. A cross-national study of the process of treatment and outcomes of major depressive disorder. J Nerv Ment Dis 1991;179:55-63.

20. Glick ID, Burti L, Suzuki K, Sacks M. Effectiveness in psychiatric care: IV. Achieving effective medication management for major affective disorder. Psychopharmacol Bull 1992;28:257-259.

21. Glick ID, Clarkin JF, Haas GL, Spencer JH. Clinical significance of inpatient family intervention: VII. Conclusions from the clinical trial. Hosp Commun Psychiatry 1993;9:869-873.

22. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford Press;1990.

23. Kane JM, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenia: A double-blind comparison versus chlorpromazine/benztropine. Arch Gen Psychiatry 1988;45:789.

24. Kane JM, Woerner MG, Sarantakos S. Depot neuroleptics: a comparative review of standard, intermediate, and low dose regiments. J Clin Psychiatry 1986;47:30-33.

25. Keck PE Jr, McElroy SL, Tugrul KC, Bennett JA. Valproate oral loading in the treatment of acute mania. J Clin Psychol 1993;54:305-308.

26. Keller MB, Shapiro RW, Lavori PW, Wolfe N. Relapse in major affective disorders. Arch Gen Psychiatry 1982;39:911-915.

27. Kinon BJ, Kane JM, Johns C et al. Treatment of neuroleptic-resistant schizophrenia relapse. Psychopharmacol Bull 1993;29:309-314.

28. Kupfer DJ, Frank E. The minimum length of treatment for recovery. In:Montgomery S, Rouillon F, eds. Long-term treatment of depression. New York: John Wiley; 1992:33-52.

29. Lewander T, Westerberg SE, Morrison D. Clinical profile of remoxipride—A combined analysis of a comparative double-blind multicenter trial programme. Acta Psychiatr Scand 1990;82:92-98.

30. Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PR. Low and conventional dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 1987;44:510-517.

31. Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, Lebell M, Zimmerman K, Liberman RP. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry 1996;153:1585-1592.

32. Marder SR, Wirshing WC, Van Putten T, et al. Fluphenazine versus placebo supplementation for prodromal signs of relapse in schizophrenia. Arch Gen Psychiatry 1994;51:280-287.

33. Martinez-Cano H, Vela-Bueno A, de Iceta M, Pomolima R, Martinez-Gras I. Benzodiazepine withdrawal syndrome seizures. Pharmacopsychiatry 1995;18:257-262.

34. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263-287.

35. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-768.

36. Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: A review of 50 years' experience. Am J Psychiatry 1994;151:169-176.

37. Petursson H. The benzodiazepine withdrawal syndrome. Addiction 1994;89:1455-1459.

38. Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, Rapaport MH. Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992;49:345-353.

39. Pitchot W, Ansseau M, Moreno Ag, Hansenne M, Jon Frenckell R. Dopaminergic function in panic disorder: comparison with major and minor depression. Biol Psychiatry 1992;32:1004-1011.

40. Post RM. Anticonvulsants and novel drugs. In: Paykel ES, ed. Handbook of affective disorders. London: Churchill Livingstone;1992:387-417.

41. Prien RF, Gelenberg AJ. Alternatives to lithium for preventive treatment of bipolar disorder. Am J Psychiatry 1989;146:840-848.

42. Reynolds CF, Frank E, Perel J, et al. Combined pharmacotherapy and psychotherapy in the acute and continuation treatment of elderly patients with recurrent major depression: a preliminary report. Am J Psychiatry 1992;149:1687-1691.

43. Robins LN, Reiger DA, eds. Psychiatric disorders in America: the epidemiologic catchment area study. New York: Free Press;1991.

44. Rouillon F. Unwanted effects of long-term treatment. In: Montgomery S, Rouillon F, eds. Long-term treatment of depression. New York: John Wiley;1992:81-112.

45. Schatzberg AF, Ballenger JC. Decisions for the clinicians in the treatment of panic disorder: when to treat, which treatment to use and how long to treat. J Clin Psychiatry 1991;52:26-31.

46. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatments. Arch Gen Psychiatry 1989;46:971-982.

47. Strauss J, Carpenter W. The prognosis of schizophrenia: rationale for a multidimensional concept. Schizophr Bull 1978;4:56-67.

48. Suppes T, Baldessarini R, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48:1082-1088.

49. Suppes T, Phillips K, Judd C. Clozapine treatment of non-psychotic rapid cycling bipolar disorder: A report of three cases. Biol Psychiatry 1994;36:338-340.

50. Task Force of the Collegium Internationale Neuro-Psychopharmacologicum (CINP). Impact of neuropharmacology in the 1990's—treatment strategies for anxiety disorders and insomnia. Eur Neuro Psychopharmacol 1992;2:167-169.

51. Thase ME. Long-term treatments of recurrent depressive disorders. J Clin Psychiatry 1992;53(Suppl):32-44.

52. Tollefson GD. Adverse drug reaction/interactions in maintenance therapy. J Clin Psychiatry 1993;54(Suppl):48-58.

53. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID. Relapse and rehospitalization during maintenance treatment of schizophrenia: The effects of dose reduction and family treatment. Arch Gen Psychiatry 1997;54:453-463..

54. Tyrer P, Hallstrom C. Antidepressants in the treatment of anxiety disorder. Psychiatr Bull 1993;17:75-76.

55. Van Putten T, May PRA, Marder SR. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981;38:187-190.

56. Waddington JL, Weller MP, Crow TJ, Hirsch SR. Schizophrenia, genetic retrenchment, and epidemiologic renaissance. Arch Gen Psychiatry 1992;49:990-994.

57. Weissman MM. Panic disorder: Impact on quality of life. J Clin Psychiatry 1991;52(Suppl):6-8.

58. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17:325-351.

59. Zarate CA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995;56:411-417.

60. Zornberg GL, Pope HG, Jr. Treatment of depression in bipolar disorder: New directions for research. J Clin Psychopharmacol 1993;13:397-408.

Back to Chapter